Form 4: Madrigal Director Taub Exercises Options, Sells Shares

Madrigal Pharmaceuticals director Rebecca Taub exercised stock options and subsequently sold 18,410 shares of common stock on January 9, 2026, pursuant to a pre-arranged trading plan.

Summary

• Rebecca Taub, a director at Madrigal Pharmaceuticals, Inc. (MDGL), executed transactions on January 9, 2026.
• She exercised stock options to acquire 18,410 shares of common stock at an exercise price of $15.8 per share.
• Concurrently, she sold all 18,410 shares of common stock acquired from the option exercise through multiple transactions.
• The sales occurred at weighted average prices ranging from $511.71 to $542.72 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 10, 2025.
• Following these transactions, Rebecca Taub directly owns 455,589 shares of common stock.
• Additionally, 655,540 shares are indirectly owned by SQN, LLC, where Taub and her spouse are managing members, with beneficial ownership disclaimed except for pecuniary interest.
• She retains beneficial ownership of 240 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, indicating a routine financial management decision rather than a lack of confidence in the company. The director realized significant gains, which is positive for the individual.

Positives

• Director Rebecca Taub realized significant gains by exercising stock options at a low price ($15.8) and selling shares at much higher market prices (ranging from $511.71 to $542.72).
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned diversification or liquidity rather than a reaction to new, non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

na

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

This Form 4 filing details an insider transaction for a director of Madrigal Pharmaceuticals, a company operating in the biotechnology and pharmaceutical sector. Such transactions are routine for executives and directors managing their personal portfolios, especially when stock options vest and are exercised, often as part of pre-planned trading strategies.

Related Party Transactions

• Rebecca Taub and her spouse are managing members of SQN, LLC, which indirectly owns 655,540 shares of Madrigal Pharmaceuticals Common Stock. Taub disclaims beneficial ownership except for her pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be interpreted in various ways, but given the 10b5-1 plan, it's likely seen as a routine personal financial management event rather than a signal of declining company prospects. The total number of shares sold (18,410) is a small fraction of the company's overall outstanding shares.
• Employees: No direct impact on employees is indicated.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of transaction does not typically signal a change in the company's fundamental prospects or warrant a strong buy/sell recommendation based solely on this filing. Investors should consider broader company performance, industry trends, and other financial disclosures for investment decisions.

Keywords

Madrigal Pharmaceuticals, MDGL, Rebecca Taub, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Director Transactions, Biotechnology, Pharmaceuticals